FDA Releases New Digital Template for Clinical Trials
Published Date: 5/22/2026
Notice
Summary
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final International Digital Protocol Standard
If you run or work at a company or research group that sponsors clinical trials, the FDA issued the final M11 CeSHarP guidance on May 22, 2026. It includes three documents (a guidance, a standardized template, and a technical specification) that set a harmonized format and data fields to share clinical trial protocol information electronically and was endorsed by the ICH Assembly in November 2025.
Guidance Is Voluntary, Not Binding
The M11 CeSHarP guidance reflects the FDA's current thinking and does not create legally enforceable duties. You may use a different approach if it still meets the applicable laws and regulations.
No New Paperwork Burden Under PRA
The guidance contains no new collection of information under the Paperwork Reduction Act and refers to existing clinical trial information collections in 21 CFR part 312 that are approved under OMB control number 0910-0014.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2026-10294 — Notice of Request for Revision to and Extension of an Information Collection; Standards for Privately Owned Quarantine Facilities for Ruminants
The USDA wants to update and keep collecting info from privately owned quarantine facilities that care for ruminants like cows and deer. This affects facility owners who must follow new rules to keep animals safe and healthy. Comments on these changes are open until July 21, 2026, and the update helps protect animals without adding big costs.
Next: 2026-10296 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and businesses to share their thoughts on how it collects information to make sure it’s useful and not too much work. They want to cut down on paperwork, especially for small businesses with fewer than 25 employees. If you want to comment, you’ve got until July 21, 2026, so don’t miss your chance to help shape smarter rules!